Pfizer Inc at Jefferies London Healthcare Conference Summary - Thomson StreetEvents

Pfizer Inc at Jefferies London Healthcare Conference Summary

Pfizer Inc at Jefferies London Healthcare Conference Summary - Thomson StreetEvents
Pfizer Inc at Jefferies London Healthcare Conference Summary
Published Nov 20, 2024
10 pages (6083 words) — Published Nov 20, 2024
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of PFE.N presentation 20-Nov-24 9:00am GMT

  
Brief Excerpt:

...Yeah. Thank you, and thank you for hosting us today. And importantly, thank you for your interest in Pfizer. I'll be very brief because we'll get right into Q&A. But I just want to state that, obviously, we went into 2024 as a company really with a keen focus on execution. I think we've continued to drive delivery of both top line and bottom line throughout this year. We continue to be very focused on enhancing and growing our Oncology franchise as well as continuing to optimize the cost structure of the organization coming off the COVID highs, now at a revenue base of about $60 billion. We're excited about the future, and we're hoping that today, we'll get a chance to both talk about what we're doing here and now, but importantly, the growth and financial outlook of the company going forward. Thank you. Akash Tewari ...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Pfizer Inc
Ticker
PFE.N
Time
9:00am GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Akash Tewari - Jefferies LLC - Analyst : Understood. So Dave, we'll start with the question that I think we've all gotten over the last few weeks or at least particularly last week with the RFK announcement and then, of course, Dr. Oz more recently heading up HHS and potentially CMS, it sounds like. I think there's been a lot of anxiety, especially when that initial announcement got through. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 20, 2024 / 9:00AM, PFE.N - Pfizer Inc at Jefferies London Healthcare Conference But I feel like from our work and I think talking to investors, there's the rhetoric and then there's the anxiety and then there's the reality. And I know you have a huge government affairs team, and I know you guys have looked at this. Can you talk about the impact, the administration change and the new appointments will have fundamentally actually on the business of Pfizer, which I think is what we really should be focusing on?

Table Of Contents

Pfizer Pflash: A Spotlight On Clostridioides difficile (C. diff) Vaccine Development Summary – 2024-12-18 – US$ 54.00 – Edited Brief of PFE.N corporate analyst meeting</ 18-Dec-24 3:00pm GMT

Pfizer Pflash: A Spotlight On Clostridioides difficile (C. diff) Vaccine Development Transcript – 2024-12-18 – US$ 54.00 – Edited Transcript of PFE.N corporate analyst meeting</ 18-Dec-24 3:00pm GMT

Pfizer Inc to Host Full-Year 2025 Guidance Call Summary – 2024-12-17 – US$ 54.00 – Edited Brief of PFE.N guidance conference call or presentation 17-Dec-24 1:30pm GMT

Pfizer Inc to Host Full-Year 2025 Guidance Call Transcript – 2024-12-17 – US$ 54.00 – Edited Transcript of PFE.N guidance conference call or presentation 17-Dec-24 1:30pm GMT

Pfizer Inc at Jefferies London Healthcare Conference Transcript – 2024-11-20 – US$ 54.00 – Edited Transcript of PFE.N presentation 20-Nov-24 9:00am GMT

Pfizer Inc at UBS Global Healthcare Conference Summary – 2024-11-13 – US$ 54.00 – Edited Brief of PFE.N presentation 13-Nov-24 8:30pm GMT

Pfizer Inc at UBS Global Healthcare Conference Transcript – 2024-11-13 – US$ 54.00 – Edited Transcript of PFE.N presentation 13-Nov-24 8:30pm GMT

Pfizer Inc Spotlight on Cancer Cachexia and Ponsegromab Summary – 2024-11-01 – US$ 54.00 – Edited Brief of PFE.N corporate analyst meeting</ 1-Nov-24 2:00pm GMT

Pfizer Inc Spotlight on Cancer Cachexia and Ponsegromab Transcript – 2024-11-01 – US$ 54.00 – Edited Transcript of PFE.N corporate analyst meeting</ 1-Nov-24 2:00pm GMT

Pfizer Inc Q3 2024 Earnings Call Summary – 2024-10-29 – US$ 54.00 – Edited Brief of PFE.N earnings conference call or presentation 29-Oct-24 2:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Pfizer Inc at Jefferies London Healthcare Conference Summary" Nov 20, 2024. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Pfizer-Inc-at-Jefferies-London-Healthcare-Conference-B16188068>
  
APA:
Thomson StreetEvents. (2024). Pfizer Inc at Jefferies London Healthcare Conference Summary Nov 20, 2024. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Pfizer-Inc-at-Jefferies-London-Healthcare-Conference-B16188068>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.